InnoSIGN specializes in Comprehensive Pathway Analysis (CPA), which leverages next-generation sequencing (NGS) to enhance patient diagnosis, stratification, and treatment. Their platform focuses on analyzing cell signaling pathways that are critical in various diseases, particularly cancer. By quantifying the activity of these pathways, InnoSIGN provides insights into the molecular mechanisms driving tumor development and response to therapies. The analysis includes measuring mRNA levels of target genes regulated by key signaling pathways, resulting in quantitative scores that characterize the molecular phenotype of tumors. This approach not only aids in patient stratification and therapy response prediction but also identifies potential resistance mechanisms and opportunities for combination therapies.

The OncoSIGNal product line further exemplifies InnoSIGN's commitment to understanding cancer biology through pathway activity profiling. This service offers a range of testing options, including RT-qPCR tests and RNA-seq data analysis, tailored to various tumor types. The OncoSIGNal portal facilitates the export of detailed reports containing pathway activity scores, which can be utilized for further data analysis and visualization. By focusing on the functional activity of critical signaling pathways such as ER, PI3K, and MAPK, InnoSIGN aims to provide actionable insights that lead to better patient outcomes and more efficient treatment strategies.

Netherlands

InnoSIGN commercializes OncoSIGNal mRNA-based tests that measure the activity of signal transduction pathways in cancer and immune cells to predict how patients will respond to targeted drugs.

InnoSIGN

Company Details